Evaluation of in vitro Effect of Pyocyanine Pigment on Interleukin-2 Secretion from Peripheral Blood Mononuclear Cells in Cancer Patients

Mohseni, Anahita; Shariat, Afsoon

doi:10.30699/ijmm.15.3.327

year 15, Issue 3 (May - Jun 2021) Iran J Med Microbiol 2021, 15(3): 327-344 | Back to browse issues page

‎ 10.30699/ijmm.15.3.327

Mendeley

Zotero

RefWorks

Mohseni A, Shariat A. Evaluation of in vitro Effect of Pyocyanine Pigment on Interleukin-2 Secretion from Peripheral Blood Mononuclear Cells in Cancer Patients. Iran J Med Microbiol 2021; 15 (3) :327-344
URL: http://ijmm.ir/article-1-1307-en.html

Evaluation of in vitro Effect of Pyocyanine Pigment on Interleukin-2 Secretion from Peripheral Blood Mononuclear Cells in Cancer Patients

Anahita Mohseni¹

, Afsoon Shariat

1- Department of Microbiology, School of Basic Sciences, Kazerun Branch, Islamic Azad University, Kazerun, Iran
2- Department of Microbiology, School of Basic Sciences, Kazerun Branch, Islamic Azad University, Kazerun, Iran , afsoonsh1980@yahoo.com

Abstract: (5068 Views)

Background and Objective: The pyocyanine pigment in Pseudomonas aeruginosa stimulates blood cells to secrete IL-2. IL-2 cytokine is an activator of cytotoxic T cells and natural killer cells. These cells destroy the target cells of patients with cancer. This study aimed to evaluate the effects of pyocyanine on the IL-2 secretion from peripheral blood mononuclear cells (PBMCs) in patients with breast, prostate, and bladder cancers.
Materials and Methods: In this cross-sectional descriptive study, a total of 30 Pseudomonas aeruginosa isolates were collected from different clinical specimens (urine, blood, burns, etc.) of patients admitted to Namazi Hospital in Shiraz, Iran, from October to December 2019. The pyocyanine was extracted from the isolates by chloroform. Also, twenty-eight peripheral blood samples were selected from 21 patients with breast, prostate, and bladder cancers and 7 healthy controls. Following the isolation of PBMCs from patients and the control group using Ficoll density gradient, samples were prepared for cell culture. Half of the PBMCs were treated with pyocyanine (0.5 μg/mL), and the rest of them remained without treatment. Then, the IL-2 secretion from the treated and untreated cells with pyocyanine was investigated by ELISA method. Statistical analysis was done using SPSS 22.
Results: Significant increases were seen in the IL-2 secretion from PBMCs in the patients with breast (P=0.032), prostate (P=0.002), bladder (P=0.009) cancers, and healthy controls (P=0.004) after treatment with pyocyanine in comparing with before treatment with this pigment in vitro.
Conclusion: Low concentrations of pyocyanine can stimulate the PBMC of cancer patients to secrete IL-2 cytokines. Further studies should be performed on the immunostimulatory effects of pyocyanine in laboratory animals.

Keywords: Cancer, Immunostimulant, Pyocyanine, Interleukin-2

Full-Text [PDF 1536 kb] (1108 Downloads) | | Full-Text (HTML) (1939 Views)

Type of Study: Original Research Article | Subject: Molecular Microbiology
Received: 2021/03/27 | Accepted: 2021/05/2 | ePublished: 2021/06/28

References

1. Knox SS. From omics to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int. 2010;10:11. [DOI:10.1186/1475-2867-10-11] [PMID] [PMCID]

2. Noori Daloii MR, Sadr Z. Cancer immunotherapy: Use the immune system to fight cancer. J Sabzevar Uni Med Sci. 2020;26(1):1-11.

3. Marrazzo E, Frusone F, Milana F, Sagona A, Gatzemeier W, Barbieri E, et al. Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single cancer analysis. Breast. 2020;49:87-92. [DOI:10.1016/j.breast.2019.11.002 [DOI:10.1016/j.breast.2019.11.002] [PMID] [PMCID]

4. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev. 2016;17(2):839-43. [DOI:10.7314/APJCP.2016.17.2.839] [PMID]

5. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309-16.

6. Rezaianzadeh A, Mohammadbeigi A, Moballeghi J, Mohammadsalehi N. Survival analysis of patients with bladder cancer, life table approach. J Midlife Health. 2012;3(2):88-92. [DOI:10.4103/0976-7800.104468] [DOI:10.4103/0976-7800.104468] [PMID] [PMCID]

7. Song S, Vuai MS, Zhong M. The role of bacteria in cancer therapy - enemies in the past, but allies at present. Infect Agent Cancer. 2018;13:9. [DOI:10.1186/s13027-018-0180-y] [PMID] [PMCID]

8. El-Fouly MZ, Sharaf AM, Shahin AAM, El-Bialy HA, Omara AMA. Biosynthesis of pyocyanin pigment by Pseudomonas aeruginosa. J Radiat Res Appl Sci. 2015;8(1):36-48. [DOI:10.1016/j.jrras.2014.10.007]

9. Zhao J, Wu Y, Alfred AT, Wei P, Yang S. Anticancer effects of pyocyanin on HepG2 human hepatoma cells. Lett Appl Microbiol. 2014;58(6):541-8. [DOI:10.1111/lam.12224] [PMID]

10. Ulmer AJ, Pryjma J, Tarnok Z, Ernst M, Flad HD. Inhibitory and stimulatory effects of Pseudomonas aeruginosa pyocyanin on human T and B lymphocytes and human monocytes. Infect Immun. 1990;58(3):808-15. [DOI:10.1128/iai.58.3.808-815.1990] [PMID] [PMCID]

11. Lissoni P. Therapy implications of the role of Interleukin-2 in cancer. Expert Rev Clin Immunol. 2017;13(5):491-8. [DOI:10.1080/1744666X.2017.1245146] [PMID]

12. Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in cancer immunotherapy. Biomed Res Int. 2018;2018:9056173. [DOI:10.1155/2018/9056173] [PMID] [PMCID]

13. Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017;16(1):153. [DOI:10.1186/s12943-017-0721-9] [PMID] [PMCID]

14. Holt JG, Krieg NG, Sneathm PHA, Staley JT, Williams ST. Bergey's Manual of Determinative Bacteriology. 9th ed. Baltimore: Williams & Wilkins; 1994. 206-8.

15. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177-92. [DOI:10.1016/j.biotechadv.2018.11.013] [PMID]

16. Moayedi A, Nowroozi J, Akhavan Sepahi A. Cytotoxic effect of pyocyanin on human pancreatic cancer cell line. Iran J Basic Med Sci. 2018;21(8-) : 794-9.

17. Priyaja P, Jayesh P, Philip R, Bright Singh IS. Pyocyanin induced in vitro oxidative damage and its toxicity level in human, fish and insect cell lines for its selective biological applications. Cytotechnology. 2016;68(1):143-55. [DOI:10.1007/s10616-014-9765-5] [PMID] [PMCID]

18. Dieter C, Dutra Lourenco E, Emerim Lemos N. Association of long non-coding RNA and leukemia:a systematic review. Gene. 2020;735:144405. [DOI:10.1016/j.gene.2020.144405] [PMID]

19. Weckle A, Aiello AE, Uddin M, Galea S, Coulborn RM, Soliven R, et al. Rapid fractionation and isolation of whole blood components in samples obtained from a community-based setting. J Vis Exp. 2015;(105):52227. [DOI:10.3791/52227] [PMID] [PMCID]

20. Piccinini F, Tesei A, Arienti C, Bevilacqua A. Cell counting and viability assessment of 2D and 3D cell cultures: expected reliability of the trypan blue assay. Biol Proced Online. 2017;19(1):8. [DOI:10.1186/s12575-017-0056-3] [PMID] [PMCID]

21. Shahbazi S, Abolhasani A. Immunostimulants: types and functions. J Med Microbiol Infec Dis. 2016;4(3-4):45-51. [URL:http://jommid.pasteur.ac.ir/article-1-131-en.htm]

22. Rada B, Gardina P, Myers TG, Leto TL. Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin. Mucosal Immunol. 2011;4(2):158-71. [DOI:10.1038/mi.2010.62] [PMID] [PMCID]

23. Venegas FA, Köllisch G, Mark K, Diederich WE, Kaufmann A, Bauer S, Chavarría M, Araya JJ, García-Piñeres AJ. The bacterial product violacein exerts an immunostimulatory effect via TLR8. Sci Rep. 2019; 9(1):13661. [DOI:10.1038/s41598-019-50038-x] [PMID] [PMCID]

24. Azman AS, Mawang CI, Abubakar S. Bacterial Pigments: The bioactivities and as an blternative for therapeutic applications. Nat Prod Commun. 2018;13(12):1747-54. [DOI:10.1177/1934578X1801301240]

25. Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451-8. [DOI:10.4049/jimmunol.1490019] [PMID] [PMCID]

26. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297-302. [DOI:10.2174/092986710793176410] [PMID]

27. Askeland EJ, Newton MR, O'Donnell MA, Luo Y. Bladder cancer immunotherapy: BCG and beyond. Adv Urol. 2012;2012:181987. [DOI:10.1155/2012/181987] [PMID] [PMCID]

28. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther. 2007;15(6):1042-52. [DOI:10.1038/sj.mt.6300162] [PMID]

29. Repka T, Chiorean E, Gay J, Herwig K, Kohl K, Yee D, et al. Trastuzumab and Interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res. 2003;9(7):2440-6.

30. Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med. 2014;12:262. [DOI:10.1186/s12967-014-0262-6] [PMID] [PMCID]